As of 2025-05-18, the Intrinsic Value of Coherus BioSciences Inc (CHRS) is 4.72 USD. This CHRS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.76 USD, the upside of Coherus BioSciences Inc is 520.00%.
The range of the Intrinsic Value is 3.10 - 8.15 USD
Based on its market price of 0.76 USD and our intrinsic valuation, Coherus BioSciences Inc (CHRS) is undervalued by 520.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 3.10 - 8.15 | 4.72 | 520.0% |
| DCF (Growth 10y) | 3.04 - 7.23 | 4.40 | 477.8% |
| DCF (EBITDA 5y) | 2.37 - 4.50 | 2.97 | 289.9% |
| DCF (EBITDA 10y) | 2.90 - 5.18 | 3.60 | 372.9% |
| Fair Value | 1.23 - 1.23 | 1.23 | 61.58% |
| P/E | 3.16 - 6.13 | 4.37 | 474.8% |
| EV/EBITDA | (7.42) - 6.53 | (1.29) | -270.0% |
| EPV | (14.37) - (18.48) | (16.43) | -2258.4% |
| DDM - Stable | 0.86 - 2.31 | 1.58 | 108.2% |
| DDM - Multi | 0.57 - 1.36 | 0.82 | 8.0% |
| Market Cap (mil) | 88.22 |
| Beta | 1.30 |
| Outstanding shares (mil) | 115.92 |
| Enterprise Value (mil) | 255.90 |
| Market risk premium | 4.60% |
| Cost of Equity | 16.80% |
| Cost of Debt | 6.81% |
| WACC | 7.72% |